Clinical observation of docetaxel in the treatment of non-small cell lung cancer and breast cancer

Xuezhi Hao, Xiangru Zhang, Yan Sun

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate the efficacy and safety of docetaxel (Wanle) and docetaxel (Wanle) plus cisplatin regimen in patients with breast cancer and non-small cell lung cancer. Methods: 1) Single agent regimen: patients of breast cancer (group A) and NSCLC (group B)were treated with docetaxel 75mg/m 2 in the first day, and the schedule was repeated every 21 days. 2) Combination regimen: patients with breast cancer were randomly assigned to receive docetaxel (Wanle) 70mg/m 2 iv + cisplatin 80mg/m 2 (group C) treatment or taxotere 70mg/m 2 iv + cisplatin 80mg/m 2 iv treatment (group D), the schedule was repeated every 21 days. Patients with NSCLC were also randomly assigned to regimens of docetaxel (Wanle)+cisplatin (group E) and Taxotere + cisplatin (group F). Results: A total of 138 of the 147 patients were evaluative for efficacy and 141 of the patients were evaluative for side effects. Overall response rate of group A, B, C, D, E , F was 21.7%, 6.1%, 60.0%, 35%, 23.8% and 28.6%, respectively. The major side effects were myelosuppression, neutropenia, nausea, vomiting and alopecia. Conclusion: The docetaxel (Wanle) is effective and well tolerated in the treatment of advanced NSCLC and breast cancer. Efficacy and side effect of docetaxel (Wanle) are similar to the imported Taxotere.

Original languageEnglish
Pages (from-to)1064-1066
Number of pages3
JournalChinese Journal of Clinical Oncology
Volume32
Issue number18
StatePublished - 2005

Keywords

  • Breast cancer
  • Docetaxel
  • Non-small cell lung cancer

Fingerprint

Dive into the research topics of 'Clinical observation of docetaxel in the treatment of non-small cell lung cancer and breast cancer'. Together they form a unique fingerprint.

Cite this